Potential strategies utilised by papillomavirus to evade host immunity

被引:81
作者
Frazer, IH [1 ]
Thomas, R
Zhou, JA
Leggatt, GR
Dunn, L
McMillan, N
Tindle, RW
Filgueira, L
Manders, P
Barnard, P
Sharkey, M
机构
[1] Univ Queensland, Princess Alexandra Hosp, Ctr Immunol & Canc Res, Dept Med, Brisbane, Qld 4102, Australia
[2] Royal Childrens Hosp, Sir Albert Sakzewski Virus Res Ctr, Herston, Qld, Australia
[3] Univ Zurich, Inst Anat, Div Cell Biol, CH-8006 Zurich, Switzerland
关键词
D O I
10.1111/j.1600-065X.1999.tb01288.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The co-evolution of papillomaviruses (PV) and their mammalian hosts has produced mechanisms by which PV might avoid specific and non-specific host immune responses. Low level expression of PV proteins in infected basal epithelial cells, together with an absence of inflammation and of virus-induced cell lysis, restricts the opportunity for effective PV protein presentation to immunocytes by dendritic cells. Additionally, PV early proteins, by a range of mechanisms, may restrict the efficacy of antigen presentation by these cells. Should an immune response be induced to PV antigens, resting keratinocytes (KC) appear resistant to interferon-gamma-enhanced mechanisms of cytotoxic T-lymphocyte (CTL)-mediated lysis, and expression of PV antigens by resting KC can tolerise PV-specific CTL. Thus, KC, in the absence of inflammation, may represent an immunologically privileged site for PV infection. Together, these mechanisms play a parr in allowing persistence of PV-induced proliferative skin lesions for months to years, even in immunocompetent hosts.
引用
收藏
页码:131 / 142
页数:12
相关论文
共 84 条
[1]   Control of neonatal tolerance to tissue antigens by peripheral T cell trafficking [J].
Alferink, J ;
Tafuri, A ;
Vestweber, D ;
Hallmann, R ;
Hämmerling, GJ ;
Arnold, B .
SCIENCE, 1998, 282 (5392) :1338-1341
[2]   T cell tolerance and activation to a transgene-encoded tumor antigen [J].
Antoniou, A ;
McCormick, D ;
Scott, D ;
Yeoman, H ;
Chandler, P ;
Mellor, A ;
Dyson, J .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1996, 26 (05) :1094-1102
[3]  
Arany I, 1995, ANTICANCER RES, V15, P2865
[4]  
Bachmann MF, 1998, J IMMUNOL, V161, P5791
[5]   DIFFERENTIAL PROMOTER UTILIZATION BY THE BOVINE PAPILLOMAVIRUS IN TRANSFORMED-CELLS AND PRODUCTIVELY INFECTED WART TISSUES [J].
BAKER, CC ;
HOWLEY, PM .
EMBO JOURNAL, 1987, 6 (04) :1027-1035
[6]   ANTIGEN PRESENTATION BY KERATINOCYTES INDUCES TOLERANCE IN HUMAN T-CELLS [J].
BAL, V ;
MCINDOE, A ;
DENTON, G ;
HUDSON, D ;
LOMBARDI, G ;
LAMB, J ;
LECHLER, R .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1990, 20 (09) :1893-1897
[7]   DIFFERENTIATION-SPECIFIC ALTERNATIVE SPLICING OF BOVINE PAPILLOMAVIRUS LATE MESSENGER-RNAS [J].
BARKSDALE, SK ;
BAKER, CC .
JOURNAL OF VIROLOGY, 1995, 69 (10) :6553-6556
[8]   A role for endogenous transforming growth factor beta 1 in Langerhans cell biology: The skin of transforming growth factor beta 1 null mice is devoid of epidermal Langerhans cells [J].
Borkowski, TA ;
Letterio, JJ ;
Farr, AG ;
Udey, MC .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 184 (06) :2417-2422
[9]   A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer [J].
Borysiewicz, LK ;
Fiander, A ;
Nimako, M ;
Man, S ;
Wilkinson, GWG ;
Westmoreland, D ;
Evans, AS ;
Adams, M ;
Stacey, SN ;
Boursnell, MEG ;
Rutherford, E ;
Hickling, JK ;
Inglis, SC .
LANCET, 1996, 347 (9014) :1523-1527
[10]   CULTURED MOUSE KERATINOCYTE ALLOGRAFTS PRIME FOR ACCELERATED 2ND SET REJECTION AND ENHANCED CYTOTOXIC LYMPHOCYTE-RESPONSE [J].
CAIRNS, BA ;
DESERRES, S ;
MATSUI, M ;
FRELINGER, JA ;
MEYER, AA .
TRANSPLANTATION, 1994, 58 (01) :67-72